Boehringer-Ingelheim was founded in Ingelheim, Germany, in 1885. The company under Albert Boehringer established a reputation for social enlightenment and tehnologically innovative products. Boehringer introduced benefits to his workforce deemed 'remarkably enlightened and generous for the time', including a health insurance scheme in 1902, annual holiday entitlement employee travel subsidiaries in 1910, and a company pension in 1912.
Boehringer-Ingelheim Pharmaceuticals focuses largely on human pharmaceuticals (prescription medicines, consumer health care and biopharmaceuticals. Specific areas of interest are: acute coronary disease, arthritis, COPD, HIV/AIDS, Hypertension, Parkinson’s Disease, Restless Legs Syndrome, Stoke and Thromboembolic Diseases. Wellknown products include Antistax, Buscopan and Dulcolax.
Boehringher Ingelheim took $10.84bn in global sales and spent $1,14bn on research and design in 2005.
Lobbying and PR firms
- : http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1.htm (Boehringer-Ingelheim history)
- http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1_3.htm (Boehringer-Ingelheim, Social Welfare Pioneer),
- http://www.boehringer-ingelheim.com/corporate/products/index.asp (Boehringer-Ingelheim products)
- Gray, N. (2006) Changing Landscapes: A special Report on the World’s Top 50 Pharma Companies, Pharmaceutical Executive. Available online at: pharmexec.findpharma.com/pharmexec/2005-Pharm-Exec-50-revised/ArticleStandard/Article/detail/354138
- Register 1st September 2014 - 30th November 2014 APPC, accessed 28 January 2015